{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:58Z","timestamp":1792719898913,"version":"4.5.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer-associated fibroblasts (CAFs) are significant contributors to the establishment of the immunosuppressive tumor microenvironment (TME) and pose a significant challenge to the effectiveness of successful immunotherapy. CAFs can secrete cytokines, chemokines, and extracellular matrix components; inhibit the invasion of immune cells; promote regulatory cell populations; and induce T cell exclusion phenotypes, thereby lowering the effectiveness of immune checkpoint inhibitors (ICIs). With the development of the field of nanotechnology, increasing studies have paid attention to employing nano-strategies to specifically control and target CAFs. These nanoplatforms can transport therapeutic cargos, e.g., CAF-toxic chemicals, signal regulators, or phenotype-modifying agents, precisely to CAFs, respectively, lowering systemic toxicity. Furthermore, the combination therapy of CAF-targeting nanoparticles and immune checkpoint inhibitors had, in preclinical scenarios, the synergistic effect of promoting T cell infiltration, antigen presentation, and cytotoxicity. However, heterotypic CAF subpopulations, inconsistency of different cancer models, inefficient cargo delivery, and translatability constraints in the clinic are serious challenges. Development of multifunctional and stimulus-active nanomedicine has great potential to overcome these challenges. Initial clinical trials, including fibroblast activation protein (FAP)-targeted CAR-T cells and antibody-drug conjugates, highlight the increasing translational potential of CAF-targeted nano-immunotherapy. This review summarizes the current progress in CAF-targeted nano-immunotherapy, emphasizing that a comprehensive molecular understanding and thorough clinical validation are essential for facilitating its clinical application in the treatment of solid malignancies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1668199","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:20:28Z","timestamp":1757391628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Nano-strategies targeting cancer-associated fibroblasts to enhance immunotherapy and reverse resistance"],"prefix":"10.3389","volume":"16","author":[{"given":"Juqing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ccell.2022.09.011","article-title":"Technology meets TILs: Deciphering T cell function in the-omics era","volume":"41","author":"Hudson","year":"2023","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1038\/s41467-024-53908-9","article-title":"Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer Malignancy","volume":"15","author":"Forsthuber","year":"2024","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115432","article-title":"The tumor microenvironment is an ecosystem sustained by metabolic interactions","volume":"44","author":"Kay","year":"2025","journal-title":"Cell Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00740-4","article-title":"CAF-induced physical constraints controlling T cell state and localization in solid tumours","volume":"24","author":"Arpinati","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.02.018","article-title":"Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression","volume":"361","author":"Luo","year":"2015","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.029447","article-title":"A peek into cancer-associated fibroblasts: origins, functions and translational impact","volume":"11","author":"LeBleu","year":"2018","journal-title":"Dis Model Mech"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.11.005","article-title":"Functional heterogeneity of fibroblasts in primary tumors and metastases","volume":"11","author":"Cheng","year":"2025","journal-title":"Trends Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.016","article-title":"Fibroblasts in cancer: unity in heterogeneity","volume":"186","author":"Chhabra","year":"2023","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduction Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.09.009","article-title":"Fibroblasts fuel immune escape in the tumor microenvironment","volume":"5","author":"De Jaeghere","year":"2019","journal-title":"Trends Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1038\/s41467-022-30306-7","article-title":"Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1038\/s41467-023-39035-x","article-title":"Nanovesicles loaded with a TGF-\u03b2 receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","article-title":"Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Pei","year":"2023","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1602452","article-title":"Role of TGF\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy","volume":"15","author":"Hou","year":"2025","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32278","article-title":"Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121844","article-title":"Dual tumor-and subcellular-targeted photodynamic therapy using glucose-functionalized MoS2 nanoflakes for multidrug-resistant tumor ablation","volume":"290","author":"Xu","year":"2022","journal-title":"Biomaterials"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/admi.202102315","article-title":"Glycosylated MoS2 sheets for capturing and deactivating E. coli bacteria: combined effects of multivalent binding and sheet size","volume":"9","author":"Xu","year":"2022","journal-title":"Adv Mater Interfaces"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1038\/s41467-024-52416-0","article-title":"Transvascular transport of nanocarriers for tumor delivery","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2215308120","DOI":"10.1073\/pnas.2215308120","article-title":"Dendrimer nanosystems for adaptive tumor-assisted drug delivery via extracellular vesicle hijacking","volume":"120","author":"Jiang","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1038\/s41467-019-11235-4","article-title":"Bioinspired lipoproteins-mediated photothermia remodels tumor stroma to improve cancer cell accessibility of second nanoparticles","volume":"10","author":"Tan","year":"2019","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine","volume":"244","author":"Danhier","year":"2016","journal-title":"J Control Release"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1038\/s41467-022-31928-7","article-title":"Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b04857","article-title":"Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem","volume":"13","author":"Lang","year":"2019","journal-title":"ACS Nano"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00712","article-title":"Preparation and bioevaluation of 99mTc-labeled FAP inhibitors as tumor radiotracers to target the fibroblast activation protein","volume":"19","author":"Ruan","year":"2022","journal-title":"Mol Pharm"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092027","article-title":"Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers","volume":"9","author":"Kaps","year":"2020","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1039\/d2tb02253b","article-title":"Cancer-associated fibroblast-targeted nanodrugs reshape colorectal tumor microenvironments to suppress tumor proliferation, metastasis and improve drug penetration","volume":"11","author":"Shen","year":"2023","journal-title":"J Mater Chem B"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02639-1","article-title":"Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity","volume":"130","author":"Akai","year":"2024","journal-title":"Br J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472","article-title":"Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis","volume":"79","author":"Mizutani","year":"2019","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3840","article-title":"The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets","volume":"16","author":"Sleeboom","year":"2024","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.7150\/thno.36936","article-title":"TGF-\u03b2 inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity","volume":"10","author":"Panagi","year":"2020","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188901","article-title":"Epigenetic regulation of cancer-associated fibroblast heterogeneity","volume":"1878","author":"Kehrberg","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.02.040","article-title":"Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy","volume":"321","author":"Yu","year":"2020","journal-title":"J Control Release"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b12025","article-title":"Biodegradable, hydrogen peroxide, and glutathione dual responsive nanoparticles for potential programmable paclitaxel release","volume":"140","author":"Chen","year":"2018","journal-title":"J Am Chem Soc"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-022-34744-1","article-title":"Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models","volume":"13","author":"Panagi","year":"2022","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122253","article-title":"Synchronous targeted delivery of TGF-\u03b2 siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment","volume":"301","author":"Yang","year":"2023","journal-title":"Biomaterials"},{"key":"B55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40824-023-00470-y","article-title":"Engineering TGF-\u03b2 inhibitor-encapsulated macrophage-inspired multi-functional nanoparticles for combination cancer immunotherapy","volume":"27","author":"Kim","year":"2023","journal-title":"Biomater Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41698-024-00556-3","article-title":"Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy","volume":"8","author":"Corvigno","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.biomaterials.2018.04.039","article-title":"Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase","volume":"171","author":"Guan","year":"2018","journal-title":"Biomaterials"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1038\/s41467-023-42509-7","article-title":"Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2209260120","article-title":"Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment","volume":"120","author":"He","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2024.102743","article-title":"Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors","volume":"58","author":"Liu","year":"2024","journal-title":"Nanomedicine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e57243","DOI":"10.7554\/eLife.57243","article-title":"Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy","volume":"9","author":"Barrett","year":"2020","journal-title":"eLife"},{"key":"B63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduction Target Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40364-025-00778-y","article-title":"Targeting the chemokine receptor CXCR4 for cancer therapies","volume":"13","author":"Rueda","year":"2025","journal-title":"biomark Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1900368116","article-title":"Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer","volume":"116","author":"Sledge","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1038\/s41598-025-89882-5","article-title":"Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy","volume":"15","author":"Ciavattone","year":"2025","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202418240","article-title":"Metabolic reprogramming of cancer-associated fibroblasts: transforming tumor accomplices into immunotherapeutic allies","volume":"35","author":"Qi","year":"2025","journal-title":"Adv Funct Mater"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c01499","article-title":"Breaking physical barrier of fibrotic breast cancer for photodynamic immunotherapy by remodeling tumor extracellular matrix and reprogramming cancer-associated fibroblasts","volume":"8","author":"Qiu","year":"2024","journal-title":"ACS Nano"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c13277","article-title":"Spatial regulation of cancer-associated fibroblasts and tumor cells via pH-responsive bispecific antibody delivery for enhanced chemo-immunotherapy synergy","volume":"19","author":"Liu","year":"2025","journal-title":"ACS Nano"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e2301257","DOI":"10.1002\/adma.202301257","article-title":"Targeted reprogramming of vitamin B(3) metabolism as a nanotherapeutic strategy towards chemoresistant cancers","volume":"35","author":"Guo","year":"2023","journal-title":"Adv Mater"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e2401304","DOI":"10.1002\/adma.202401304","article-title":"Dendritic polymer-based nanomedicines remodel the tumor stroma: improve drug penetration and enhance antitumor immune response","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv Mater"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.02.041","article-title":"Safe engineering of cancer-associated fibroblasts enhances checkpoint blockade immunotherapy","volume":"356","author":"Geng","year":"2023","journal-title":"J Control Release"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-022-34744-1","article-title":"Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models","volume":"13","author":"Panagi","year":"2022","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1038\/s41467-022-30306-7","article-title":"Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk3074","article-title":"Modulating tumoral exosomes and fibroblast phenotype using nanoliposomes augments cancer immunotherapy","volume":"10","author":"Freag","year":"2024","journal-title":"Sci Adv"},{"key":"B77","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908626116","article-title":"Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells","volume":"116","author":"Tian","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557698","article-title":"Heterogenous cancer-associated fibroblasts related tumor microenvironment marked by CD10\/KLF4\/TIAM1 were identified in pancreatic adenocarcinoma by integrated transcriptomics","volume":"16","author":"Wan","year":"2025","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2023.10.017","article-title":"Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives","volume":"32","author":"Shen","year":"2024","journal-title":"Bioact Mater"},{"key":"B81","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for Malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduction Target Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268689","article-title":"Preclinical evaluation of 68Ga\/177Lu-labeled FAP-targeted peptide for tumor radiopharmaceutical imaging and therapy","volume":"66","author":"Wang","year":"2025","journal-title":"J Nucl Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduction Target Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:20:29Z","timestamp":1757391629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2025.1668199"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1668199","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1668199"}}